Cite

HARVARD Citation

    Tarhini, A. et al. (n.d.). 312 Female sex independently predicts adjuvant immunotherapeutic benefit from CTLA4 immune checkpoint inhibition. Journal for immunotherapy of cancer. p. A339. [Online]. 
  
Back to record